ERBB2 and breast carcinoma: Hetero- and homozygous TP53 mutation R248W (linked with aggressive characteristics and drug resistance) in single CTCs and CTCs clusters from one ER+/PR-/HER2- metastatic breast cancer patient, confirmed in the matched primary tumour, was also reported by Mu et al. [119].